Dr. Larry Jack New Jr. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 210 Logan St, Williamson, WV 25661 Phone: 304-235-3535 |
Rebecca Ashley Mcpherson, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 859 Alderson St, Williamson, WV 25661 Phone: 304-899-6132 |
Hershel Baker Jr., PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 54 W 2nd Ave, Williamson, WV 25661 Phone: 304-235-3784 |
Samuel Randolph Ballengee, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 54 W 2nd Ave, Williamson, WV 25661 Phone: 304-475-0080 Fax: 304-475-0080 |
Mr. Perry Joseph Ayoob, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 859 Alderson St, Williamson, WV 25661 Phone: 304-899-6131 |
Mr. Joseph Lee Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 54 W 2nd Ave, Williamson, WV 25661 Phone: 304-235-8080 |
Larry David Simpkins, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 859 Alderson St, Williamson, WV 25661 Phone: 304-899-6131 Fax: 304-235-6195 |
Charles Baisden Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 859 Alderson St, Williamson, WV 25661 Phone: 304-235-2500 |
Mrs. Nicole Mcnamee, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 215 Logan St, Williamson, WV 25661 Phone: 304-235-3535 Fax: 304-235-1258 |
News Archive
New research suggests that cesarean births for transplant patients carry higher risks to baby and mother.
Arpida Ltd. has announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for intravenous iclaprim for the treatment of complicated skin and skin structure infections (cSSSI).
WHO is surging additional medical supplies and health workers into the earthquake-affected region to help the Government of Nepal provide rapid medical assistance to the thousands who have been injured in Saturday's disaster.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.
› Verified 2 days ago